FDA Approves the First Treatment for ADPKD

Living with PKD | Newly Diagnosed
Back to Search
Recorded April 2018

In this webinar, learn about JYNARQUE™ (tolvaptan), the new FDA-approved treatment for ADPKD. Hosted by Ronald Perrone, M.D., Associate Chief, Division of Nephrology at Tufts Medical Center and Professor of Medicine at Tufts University School of Medicine. 

Originally aired April 2018

Related Resources

COVID-19 Update

COVID-19 Update

Tuesday, September 21, 2021 | 7 p.m. CDT

Learn about the current recommendations surrounding COVID-19 and immunocompromised individuals.

Learning Objective(s):
—Understand the implications of the Delta variant of COVID.
—Learn precautions needed against the Delta variant of COVID.
—Discuss the current CDC recommendations regarding COVID and immunocompromised individuals

Latest discoveries in ADPKD genetics

Latest discoveries in ADPKD genetics

Tuesday, September 28, 2021 | 7 p.m. CST

What is the database and what are we learning from it?

Learning Objective(s):
—Understand how genetic test results can tell us about a PKD patient’s disease progression.
—Learn how to sign up to participate in genetic research.
—Increase knowledge of PKDF’s funded research programs and projects